New combo tackles tough myeloma: early trial seeks safer doses
NCT ID NCT07280013
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-stage study is testing a new two-drug combination (cemsidomide plus elranatamab) in about 60 people whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to find a safe dose and see if the combination can shrink the cancer. Participants will take cemsidomide pills for two weeks on and two weeks off, plus regular injections of elranatamab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner MD Anderson Cancer Center
NOT_YET_RECRUITINGGilbert, Arizona, 85234, United States
-
Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITINGLebanon, New Hampshire, 03756, United States
-
Duke Cancer Center
NOT_YET_RECRUITINGDurham, North Carolina, 27710, United States
-
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
-
Indiana University
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
-
Loyola University Medical Center
NOT_YET_RECRUITINGMaywood, Illinois, 60153, United States
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10021, United States
-
Norton Cancer Institute St. Matthews
NOT_YET_RECRUITINGLouisville, Kentucky, 40207, United States
-
Perlmutter Cancer Center at NYU Langone Hospital
NOT_YET_RECRUITINGBrooklyn, New York, 11203, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Tampa General Hospital
NOT_YET_RECRUITINGTampa, Florida, 33606, United States
-
UCLA Health, Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITINGSanta Monica, California, 90404, United States
-
University of Maryland Greenbaum Comprehensive Cancer Center
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
-
University of Nebraska
NOT_YET_RECRUITINGOmaha, Nebraska, 68105, United States
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.